Berberine and LGD-4033 Interaction

Avoid
Mechanism-based 64% confidence

Berberine and LGD-4033 have a potentially harmful interaction with 64% confidence. Both Berberine and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

Berberine

Plant Alkaloid | Natural Glucose & Lipid Management

Berberine's primary mechanism of action involves activation of AMP-activated protein kinase (AMPK), the cell's master energy-sensing enzyme. Unlike metformin, which activates AMPK primarily through inhibition of mitochondrial Complex I, berberine appears to activate AMPK through multiple pathways, including direct inhibition of mitochondrial Complex I, stimulation of AMPK phosphorylation, and modulation of the AMP-to-ATP ratio.

Half-life: ~4 hours Typical dose: 500 mg 2-3x/day metabolic, longevity
ampkngf blood pressure raisinghepatotoxicinsulin disruptinginsulin sensitizing
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pancreas
low

Shared Safety Flags

2x 2 compounds raise blood pressure (Berberine, LGD-4033). Monitor BP daily and consider cardiovascular support.
2x 2 hepatotoxic compounds (Berberine, LGD-4033). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Berberine, LGD-4033). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Berberine, LGD-4033). Monitor accordingly.

Frequently Asked Questions

Can I take Berberine with LGD-4033?

Combining Berberine with LGD-4033 is not recommended. Both Berberine and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Berberine and LGD-4033 safe together?

This combination carries significant risk. Both Berberine and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Berberine and LGD-4033?

Both Berberine and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Berberine and LGD-4033?

Berberine has a half-life of ~4 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Berberine vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.